[HTML][HTML] COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
A Fendler, EGE de Vries… - Nature Reviews …, 2022 - nature.com
Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and
associated mortality than the general population. Owing to this increased risk, patients with …
associated mortality than the general population. Owing to this increased risk, patients with …
Clinical course and management of COVID-19 in the era of widespread population immunity
The clinical implications of COVID-19 have changed since SARS-CoV-2 first emerged in
humans. The current high levels of population immunity, due to prior infection and/or …
humans. The current high levels of population immunity, due to prior infection and/or …
Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in …
M Mikulska, C Sepulcri, C Dentone… - Clinical Infectious …, 2023 - academic.oup.com
Background Severely immunocompromised patients are at risk for prolonged or relapsed
Coronavirus Disease 2019 (COVID-19), leading to increased morbidity and mortality. We …
Coronavirus Disease 2019 (COVID-19), leading to increased morbidity and mortality. We …
[HTML][HTML] Outcomes of the SARS-CoV-2 omicron (B. 1.1. 529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the …
Summary Background The omicron (B. 1.1. 529) variant of SARS-CoV-2 is highly
transmissible and escapes vaccine-induced immunity. We aimed to describe outcomes due …
transmissible and escapes vaccine-induced immunity. We aimed to describe outcomes due …
Outcome of early treatment of SARS‐CoV‐2 infection in patients with haematological disorders
M Mikulska, D Testi, C Russo, E Balletto… - British Journal of …, 2023 - Wiley Online Library
Outcome of early treatment of COVID‐19 with antivirals or anti‐spike monoclonal antibodies
(MABs) in patients with haematological malignancies (HM) is unknown. A retrospective …
(MABs) in patients with haematological malignancies (HM) is unknown. A retrospective …
[HTML][HTML] Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events–a retrospective …
Background Due to potentially immune-escaping virus variants and waning immunity, a third
SARS-CoV-2 vaccination dose is increasingly recommended. However, data in patients with …
SARS-CoV-2 vaccination dose is increasingly recommended. However, data in patients with …
[HTML][HTML] Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron
MJ Mair, M Mitterer, P Gattinger, JM Berger… - Cancer Cell, 2022 - cell.com
Patients with cancer are at high risk for severe clinical courses of COVID-19 and delays of
antineoplastic treatment due to SARS-CoV-2 infections (Pinato et al., 2022). SARS-CoV-2 …
antineoplastic treatment due to SARS-CoV-2 infections (Pinato et al., 2022). SARS-CoV-2 …
[HTML][HTML] Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer
DJ Pinato, D Ferrante, J Aguilar-Company… - European Journal of …, 2022 - Elsevier
Abstract Background Although SARS-CoV-2 vaccines immunogenicity in patients with
cancer has been investigated, whether they can significantly improve the severity of COVID …
cancer has been investigated, whether they can significantly improve the severity of COVID …
[HTML][HTML] SARS-CoV-2 omicron (B. 1.1. 529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry
A Cortellini, J Tabernero, U Mukherjee… - The Lancet …, 2023 - thelancet.com
Background COVID-19 sequelae can affect about 15% of patients with cancer who survive
the acute phase of SARS-CoV-2 infection and can substantially impair their survival and …
the acute phase of SARS-CoV-2 infection and can substantially impair their survival and …
Association of SARS-CoV-2 spike protein antibody vaccine response with infection severity in patients with cancer: a national COVID cancer cross-sectional …
Importance Accurate identification of patient groups with the lowest level of protection
following COVID-19 vaccination is important to better target resources and interventions for …
following COVID-19 vaccination is important to better target resources and interventions for …